Istari Oncology
Dr. Nichols most recently served as Chief Medical Officer for Chimerix, Inc., where he led the development efforts for dociparstat sodium, an investigational, intravenous treatment in development as first-line therapy in acute myeloid leukemia (AML), and brincidofovir, an oral antiviral currently being developed for the treatment of smallpox. Previously, he served as Head of Global Development at ViiV Healthcare and GlaxoSmithKline.
Dr. Nichols spent four years on the faculty of the Fred Hutchinson Cancer Research Center in Seattle, Washington, where he was the principal investigator on NIH-funded grants exploring the prevention and treatment of viral infections in hematopoietic cell transplant (HCT) recipients. Dr. Nichols received his MD from Duke University and earned an MS in Epidemiology from the University of Washington, where he completed a Fellowship in Infectious Diseases.
This person is not in any offices
Istari Oncology
Istari Oncology, Inc. is a clinical-stage biotechnology company focused on novel immuno-oncology and immunotherapy platforms for the treatment of glioblastoma and a wide variety of tumors.